New treatment for joint pain after injuries
Engineered Biotherapeutic Agent for Treatment of Post-Traumatic Osteoarthritis
This study is testing a new gel that can be injected into joints to help reduce inflammation and protect cartilage for people who have joint injuries and are at risk of developing post-traumatic osteoarthritis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Provizigen LLC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10821518 on NIH RePORTER |
What this research studies
This research focuses on developing a novel injectable hydrogel that delivers anti-inflammatory and cartilage-protecting agents directly into the joints affected by post-traumatic osteoarthritis (PTOA). The approach involves using a protein-engineered therapeutic system called HydroGEN, which forms a gel upon injection, allowing for sustained release of the treatment. The goal is to prevent the rapid degeneration of cartilage that occurs after joint injuries and promote natural cartilage repair. Patients who have experienced joint injuries may benefit from this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have suffered acute joint injuries leading to post-traumatic osteoarthritis.
Not a fit: Patients with chronic osteoarthritis not related to recent joint injuries may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option that slows down or halts the progression of post-traumatic osteoarthritis, potentially reducing the need for joint replacement surgeries.
How similar studies have performed: Previous preclinical studies have shown promising results with similar injectable therapies in preventing the development of post-traumatic osteoarthritis.
Where this research is happening
New York, United States
- Provizigen LLC — New York, United States (Active)
Researchers
- Principal investigator: Chaugule, Jui Shivaji — Provizigen LLC
- Study coordinator: Chaugule, Jui Shivaji
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.